Roadmap to Parenthood: Testing the Efficacy of a Decision Aid and Planning Tool for Family Building After Cancer
Launched by STANFORD UNIVERSITY · Sep 15, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Roadmap to Parenthood," is exploring how a special online tool can help women who have had cancer think about and plan for having children in the future. The study aims to provide support for those who are unsure about their family-building options after cancer treatments, which can sometimes affect fertility or the ability to have children.
To participate, women must be between 18 and 45 years old, have been assigned female at birth, and have a history of cancer. They should have completed their cancer treatments and be interested in having children or exploring their options. Participants will use the online decision aid to help them make informed choices regarding family planning. If you're interested, it will be important to have internet access and be comfortable using a computer, tablet, or smartphone. The study is currently recruiting, and those selected will have the opportunity to gain valuable insights into their family planning after cancer.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Assigned female at birth
- • Aged 18 to 45 years old
- • Understands verbal and written English
- • History of a cancer diagnosis.
- • Completed cancer treatment(s) with known or uncertain gonadotoxic effects (e.g., systemic chemotherapy, surgery or radiation affecting reproductive organs or hormone regulation, stem cell or bone marrow transplant, and/or immunotherapy)
- • Interested in having a future child (or more children) or uncertain about family building plans
- • Access to the Internet and use of a computer, tablet, or smartphone
- • Ability to understand and the willingness to personally sign the written IRB-approved informed consent document
- Exclusion Criteria:
- • Currently undergoing cancer treatment excluding long term adjuvant or maintenance therapies, such as tamoxifen
- • Significant physical or mental disability that prevents completion of study activities
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Palo Alto, California, United States
Patients applied
Trial Officials
Catherine Benedict, PhD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported